{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T04:51:24Z","timestamp":1771649484807,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T00:00:00Z","timestamp":1725753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Asia-Pac J Clncl Oncology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Dendritic cell (DC) vaccines show promise for glioma treatment, but optimal use remains uncertain. This meta\u2010analysis examined DC vaccine efficacy and safety for gliomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This systematic review and meta\u2010analysis study was conducted using the Preferred Reporting Items for Systematic Reviews and Meta\u2010Analyses. From the date of inception to October 23, 2023, electronic databases PubMed, Embase, Web of Science, and Scopus have been thoroughly evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 12 studies with 998 patients and a mean age ranging from 40.2 to 56 years were included. Across 12 articles, DC vaccine 6\u2010month overall survival (OS) was 100% [95% confidence interval {95%CI}: 100%\u2013100%]. Respectively, 12\u2010month OS reported 75% [95%CI: 65%\u201385%] but declined to 32% [95%CI: 20%\u201343%] for 24\u2010month OS. 6\u2010 and 12\u2010month progression\u2010free survival reached 49% [95%CI: 21%\u201377%] and 19% [95%CI:8%\u201330%]. Studying radiological outcomes shows that complete response and partial response rates were 13% [95%CI: 17%\u201342%], and 26% [95%CI: 10%\u201342%], though stable disease reached 33% [95%CI: 15%\u201351%], suggesting predominant antineoplastic effects. The progressive disease rate also was 24% [95%CI: 9%\u201357%].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In gliomas, DC vaccinations show a temporary efficacy; stability is more prevalent than regression. Impacts favor decreased resistance to early disease. Enhancing efficacy remains critical. Early therapy can be enhanced by appropriate supplementary therapy integration.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ajco.14110","type":"journal-article","created":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T13:18:25Z","timestamp":1725801505000},"page":"671-680","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The clinical utility of autologous tumor lysate\u2010loaded dendritic cell vaccination for patients with glioma: A systematic review and meta\u2010analysis"],"prefix":"10.1111","volume":"20","author":[{"given":"Mohammad Amin","family":"Habibi","sequence":"first","affiliation":[{"name":"Department of Neurosurgery Shariati Hospital Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Sina","family":"Mirjani","sequence":"additional","affiliation":[{"name":"Student Research Committee Qom University of Medical Sciences  Qom Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Hussain","family":"Ahmadvand","sequence":"additional","affiliation":[{"name":"Student Research Committee Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pouria","family":"Delbari","sequence":"additional","affiliation":[{"name":"Student Research Committee Tehran University of Medical Sciences  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shayan","family":"Arabi","sequence":"additional","affiliation":[{"name":"School of Medicine Islamic Azad University Tehran Medical Branch  Tehran Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Poriya","family":"Minaee","sequence":"additional","affiliation":[{"name":"Student Research Committee Qom University of Medical Sciences  Qom Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"SeyedMohammad","family":"Eazi","sequence":"additional","affiliation":[{"name":"Student Research Committee Qom University of Medical Sciences  Qom Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4321-874X","authenticated-orcid":false,"given":"Sajjad","family":"Ahmadpour","sequence":"additional","affiliation":[{"name":"Patient Safety Research Center Clinical Research Institute Urmia University of Medical Sciences  Urmia Iran"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,9,8]]},"reference":[{"key":"e_1_2_21_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3505"},{"key":"e_1_2_21_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-011-9265-6"},{"key":"e_1_2_21_4_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0497"},{"key":"e_1_2_21_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0120"},{"key":"e_1_2_21_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2232-y"},{"key":"e_1_2_21_7_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2563"},{"key":"e_1_2_21_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5370"},{"key":"e_1_2_21_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-018-1507-6"},{"key":"e_1_2_21_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2011.08.020"},{"key":"e_1_2_21_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2867"},{"issue":"10","key":"e_1_2_21_12_1","first-page":"10","article-title":"Audencel immunotherapy based on dendritic cells has no effect on overall and progression\u2010free survival in newly diagnosed glioblastoma: a phase II randomized trial","author":"Buchroithner J","year":"2018","journal-title":"Cancers"},{"key":"e_1_2_21_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2010.11.034"},{"key":"e_1_2_21_14_1","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Matthew JP","year":"2021","journal-title":"BMJ"},{"key":"e_1_2_21_15_1","first-page":"241","volume-title":"Cochrane Statistical Methods Group. Analysing data and undertaking meta\u2010analyses","author":"Deeks JJ","year":"2019"},{"key":"e_1_2_21_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-03-3505"},{"key":"e_1_2_21_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12013-011-9265-6"},{"key":"e_1_2_21_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2011.08.020"},{"key":"e_1_2_21_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2010.11.034"},{"key":"e_1_2_21_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0120"},{"key":"e_1_2_21_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2563"},{"key":"e_1_2_21_22_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.5370"},{"key":"e_1_2_21_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0497"},{"key":"e_1_2_21_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2232-y"},{"key":"e_1_2_21_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers10100372"},{"key":"e_1_2_21_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2016.1218762"},{"key":"e_1_2_21_27_1","first-page":"12","article-title":"Dendritic cell vaccination of glioblastoma: road to success or dead end","author":"Datsi A","year":"2021","journal-title":"Front Immunol"},{"key":"e_1_2_21_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.wneu.2018.08.202"},{"key":"e_1_2_21_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108929"},{"key":"e_1_2_21_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106336"},{"key":"e_1_2_21_31_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01513-z"},{"key":"e_1_2_21_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2020.02.002"},{"key":"e_1_2_21_33_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noad088"}],"container-title":["Asia-Pacific Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ajco.14110","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T03:25:25Z","timestamp":1741749925000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ajco.14110"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,8]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/ajco.14110"],"URL":"https:\/\/doi.org\/10.1111\/ajco.14110","archive":["Portico"],"relation":{},"ISSN":["1743-7555","1743-7563"],"issn-type":[{"value":"1743-7555","type":"print"},{"value":"1743-7563","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,8]]},"assertion":[{"value":"2024-04-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-08-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-09-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}